Mark Freedman From University of Ottawa: Interferon Still a Viable Option for Multiple Sclerosis
FEBRUARY 19, 2016
While newer medications are constantly being developed for multiple sclerosis one of the original options may still be the best for some patients.
Mark Freedman, HBSc, MSc, MD, from the University of Ottawa, discussed what he said some have described as a "defunct" treatment option during the annual ACTRIMS conference in New Orleans. There may be a rush to go with the newest and the most innovative medications as soon as they hit the market but Freedman said interferon is an option that doctors know works and has a decades long track record to back up its success as well as identify potential adverse events.